ASCO 2022 | Reducing oral mucositis in patients treated with CRT using avasopasem manganese

Paolo Bossi, MD, University of Brescia, Brescia, Italy, discusses the results of a Phase III trial of avasopasem manganese for severe oral mucositis in patients receiving chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck cancer This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.